Intervention group: Tab Hydroxychloroquine 400 mg P.O. BID for five days plusTab Oseltamivir 75 mg P.O. BID for five days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for five days plus

2 trials

Sponsors

Shahid Beheshti University of Medical Sciences

Conditions

COVID-19 pneumonia. Confirmed diagnosis of COVID-19COVID-19 pneumonia. Coronavirus infection, unspecified

Phase 2

Evaluation the Efficacy and Safety of Tocilizumab in COVID-19

RecruitingIRCT20151227025726N13

Shahid Beheshti University of Medical SciencesCOVID-19 pneumonia. Confirmed diagnosis of COVID-19

Start: 2020-03-11Target: 40Updated: 2020-04-21

Phase 3

Evaluting the therapeutic and adverse effects of Interferon beta 1-a in patients with novel Coronavirus(COVID-19)

Active, not recruitingIRCT20151227025726N12

Shahid Beheshti University of Medical SciencesCOVID-19 pneumonia. Coronavirus infection, unspecified

Start: 2020-03-03Target: 20Updated: 2020-04-21

Related Papers

Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.

2020-06-0760 citations